<DOC>
	<DOC>NCT00333736</DOC>
	<brief_summary>Hypothesis: Patients using enfuvirtide with the Biojector have an improved quality of life, greater satisfaction, and fewer adverse events compared with using the standard needle.</brief_summary>
	<brief_title>Study to Assess Safety and Quality of Life of Patients Using Biojector Versus Needles for Fuzeon Administration</brief_title>
	<detailed_description>This study is a "N of one" trial where the patient is their own control. We will provide the quality of life questionnaire, the MOS-HIV questionnaire; ISR questionnaire and a satisfaction questionnaire to patients that have used a standard need to inject enfuvirtide for at least one month. As well, demographics and laboratory data will be collected. The same procedures will be given 1 month after the use of Biojector in a follow-up visit.</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>Patients who have taken enfuvirtide for at least one month Patients with hemophilia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Injection site reactions</keyword>
	<keyword>enfuvirtide administration</keyword>
</DOC>